Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Drug

Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment

Fineline Cube Mar 7, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...

Company Drug

Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16

Fineline Cube Mar 7, 2025

China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...

Company Drug

Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease

Fineline Cube Mar 7, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Johnson & Johnson Terminate Phase III VENTURA Program for Aticaprant in adjunctive treatment of MDD

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced the termination of the Phase III...

Company Drug

Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production

Fineline Cube Mar 7, 2025

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million...

Company Drug

Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials

Fineline Cube Mar 7, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...

Company Deals

4C Medical Lands $175M Series D to Advance AltaValve TMVR System

Fineline Cube Mar 7, 2025

US-based 4C Medical Technologies, Inc., a medical device company controlled by China-based MicroPort CardioFlow Medtech...

Company

Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences

Fineline Cube Mar 7, 2025

German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a...

Company Deals

Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform

Fineline Cube Mar 7, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...

Company Drug

Johnson & Johnson Officially Launches Spravato in China for Depression Treatment

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...

Company Drug

Abbisko Therapeutics’ ABSK131 Receives Clinical Trial Approval from China’s NMPA

Fineline Cube Mar 7, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...

Company Medical Device

Cryofocus Medtech’s Malignant Stenosis Cryoablation System Approved by NMPA for Chinese Market

Fineline Cube Mar 7, 2025

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd (HKG: 6922) has announced receiving endorsement...

Company Deals Drug

Roche and JD Healthcare Collaborate on Influenza Prevention with Xofluza (Baloxavir Marboxil)

Fineline Cube Mar 7, 2025

Swiss giant Roche’s (SWX: ROG, OTCMKTS: RHHBY) China unit has entered into a collaboration agreement...

Company Drug

Suzhou GenAssist’s GEN6050X Receives FDA Clearance for Duchenne Muscular Dystrophy Treatment

Fineline Cube Mar 7, 2025

China-based Suzhou GenAssist Therapeutic Co., Ltd has announced receiving clearance from the US Food and...

Company Drug

BioRay Biopharmaceutical’s BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies

Fineline Cube Mar 7, 2025

Zhejiang-based BioRay Biopharmaceutical has announced receiving clearance from the National Medical Products Administration (NMPA) to...

Company Drug

CStone Pharmaceuticals’ CS5001 Enters Phase Ib Trial for Diffuse Large B-Cell Lymphoma

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced a Phase Ib clinical filing in Australia for...

Company Drug

Roche’s Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment

Fineline Cube Mar 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the US Food and...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment

Fineline Cube Mar 6, 2025

China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

ImmuneOnco’s Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) has received approval from the National Medical Products...

Company Drug

CSPC Pharma’s JMT108 Receives NMPA Clinical Approval for Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced clinical approval from the National Medical...

Posts pagination

1 … 203 204 205 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.